Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • The_Roads
    Member
    • May 2009
    • 38

    Targeted amplicon sequencing, is full overlap necessary?

    Hi,

    Has anyone got experience running targeted amplicon libraries at less than full overlap?

    We have been asked to run thunderbolts libraries that recommend 2x 250 bp to achieve full overlap but we only have access to 2x 150.

    Is this a total waste of time or just not ideal?

    Ideally we'd want to reach variant frequency of <<10%

    Thanks
  • MU Core
    Member
    • Apr 2008
    • 60

    #2
    A related question...the ability to identify and remove chimeric amplicons when lacking overlapping sequences has come up for a recent data set. Does anyone have a feel for how this may impact data analysis?

    Comment

    • Brian Bushnell
      Super Moderator
      • Jan 2014
      • 2709

      #3
      You don't need a full overlap for amplicon libraries. You just need enough of an overlap to merge the reads. Depending on your read quality, a aiming for 30-50bp overlap should be fine.

      Chimeric non-overlapping amplicons are hard to detect. If you cluster your pairs, and then find pairs in which the two reads map to different clusters, then you could assume that those pairs are chimeric. But the sensitivity and specificity depend completely on the quality of clustering.

      Comment

      • The_Roads
        Member
        • May 2009
        • 38

        #4
        Thank you Brian, that makes sense.

        Comment

        • thermophile
          Senior Member
          • Apr 2015
          • 243

          #5
          The base quality will be significantly improved if you fully overlap your reads for amplicon sequencing. see http://aem.asm.org/content/79/17/511...7-5d313d15b9a5 for a comparison of the sequence quality for different lenghts of 16s sequencing.

          If you're interested in very small number of base differences, you absolutely need to fully overlap. If you need 5-10% differences, maybe you could get away with not fully overlapping. But the cost difference between the 2 kits is only a couple of hundred $, your downstream computation time will be much much greater with marginal sequences which likely will cost thousands rather than hundreds

          ETA-my cost estimate for computational time is based on 16S, I've never dealt with any of the cancer panels so don't know how significantly poor quality bases would impact your results
          Last edited by thermophile; 10-16-2015, 08:57 AM.
          Microbial ecologist, running a sequencing core. I have lots of strong opinions on how to survey communities, pretty sure some are even correct.

          Comment

          • Brian Bushnell
            Super Moderator
            • Jan 2014
            • 2709

            #6
            Originally posted by thermophile View Post
            The base quality will be significantly improved if you fully overlap your reads for amplicon sequencing. see http://aem.asm.org/content/79/17/511...7-5d313d15b9a5 for a comparison of the sequence quality for different lenghts of 16s sequencing.

            If you're interested in very small number of base differences, you absolutely need to fully overlap. If you need 5-10% differences, maybe you could get away with not fully overlapping. But the cost difference between the 2 kits is only a couple of hundred $, your downstream computation time will be much much greater with marginal sequences which likely will cost thousands rather than hundreds

            ETA-my cost estimate for computational time is based on 16S, I've never dealt with any of the cancer panels so don't know how significantly poor quality bases would impact your results
            I disagree. First off, I'm not sure what computation time you are talking about. How are you incurring thousands of dollars of compute costs from this kind of data?

            Second, the data that paper used was low quality and not indicative of what I would expect from a properly-design MiSeq 2x250 amplicon run, using staggered primers and an appropriate amount of spike-in, etc.

            Third, errors due to incorrect merges and errors in the reads themselves are conflated; since the former are due to the specific software used for overlapping, and are also a function of the overlap length, you can't really draw a conclusion about the error rates of overlapping reads using any methodology but the one described in the paper. Unfortunately, it's not described in the paper - rather, they sort of hint that it's described here, where I guess it occurs in the make.contigs command. I have not tested that, but would be very surprised if it was the best available tool for the purpose.

            Fourth, 2x150 reads have a much lower error rate than 2x250 reads. If they overlap by 50bp, then the only nonoverlapping portion is the first and last 100bp, which have around a peak 0.2% error rate for R1 and 0.5% error rate for R2 (average is lower), including all reads with no quality-filtering. Those are on HiSeq; MiSeq error rates are generally lower.

            Longer reads and longer overlaps are better, of course. But 2x150 is viable as long as there is sufficient overlap to merge, and you can tolerate a fraction of a percent error rate in the non-double-sequenced portion.

            Comment

            • thermophile
              Senior Member
              • Apr 2015
              • 243

              #7
              If you are sequencing amplicons for 16s you need to cluster the sequences into OTUs. the more sequencing errors you have the more spurious OTUs you generate-which massively increases the memory require to cluster those (assuming you are doing de novo clustering). If you get them clustered, you then will waste a lot of time trying to find meaning in the sequencing noise or you can just throw out all of the rare OTUs which means that you will be throwing out good data along with the bad because you can't tell the difference between the good and bad rares. Ecologically this matters, for a cancer panel-maybe it doesn't.
              Microbial ecologist, running a sequencing core. I have lots of strong opinions on how to survey communities, pretty sure some are even correct.

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 07-20-2026, 11:10 AM
              0 responses
              18 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-13-2026, 10:26 AM
              0 responses
              33 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-09-2026, 10:04 AM
              0 responses
              44 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-08-2026, 10:08 AM
              0 responses
              30 views
              0 reactions
              Last Post SEQadmin2  
              Working...